patrick.net
An Antidote to Corporate Media
1,190,214 comments by 13,855 users - Al_Sharpton_for_President online now
Moderna Stock Plunges 12% As Q3 Results Miss Estimates.
invite response
2022 Nov 3, 12:37pm 1,138 views 13 comments
Comments 1 - 13 of 13 Search these comments
1
Undoctored
2022 Nov 3, 1:14pm
Undoctored
2022 Nov 3, 1:14pm
This article is from a year ago (Nov 4, 2021). Not a word about boosters. Authorization of the Moderna booster was still a month away (Dec 9). So why did they say “initial two shots”?
2
Al_Sharpton_for_President
2022 Nov 3, 1:19pm
Al_Sharpton_for_President
2022 Nov 3, 1:19pm
Undoctored says
Ooops. Will update it.
This article is from a year ago (Nov 4, 2021). Not a word about boosters. Authorization of the Moderna booster was still a month away (Dec 9). So why did they say “initial two shots”?
Ooops. Will update it.
3
Undoctored
2022 Nov 3, 5:00pm
Undoctored
2022 Nov 3, 5:00pm
Hey but this is interesting. Is this an annual occurrence? For reference:
https://www.cnbc.com/2021/11/04/covid-vaccine-moderna-mrna-earnings-q3-2021.html
This is not the article originally posted. It does mention boosters. Apparently they had just been authorized for “tens of millions” of (“high risk”) Americans.
https://www.cnbc.com/2021/11/04/covid-vaccine-moderna-mrna-earnings-q3-2021.html
This is not the article originally posted. It does mention boosters. Apparently they had just been authorized for “tens of millions” of (“high risk”) Americans.
4
Al_Sharpton_for_President
2022 Nov 3, 7:34pm
Al_Sharpton_for_President
2022 Nov 3, 7:34pm
Undoctored says
I think the government buys a shit ton. Probably wasted money.
Here's the original article:
https://finance.yahoo.com/news/moderna-stock-plunges-cutting-sales-090010607.html
Not sure how third-world countries are set up logisitically to ensure correct administration of the vax. Could all be a gigantic Biden type skim operation.
This is not the article originally posted. It does mention boosters. Apparently they had just been authorized for “tens of millions” of (“high risk”) Americans.
I think the government buys a shit ton. Probably wasted money.
Here's the original article:
https://finance.yahoo.com/news/moderna-stock-plunges-cutting-sales-090010607.html
Not sure how third-world countries are set up logisitically to ensure correct administration of the vax. Could all be a gigantic Biden type skim operation.
6
Onvacation
2023 Apr 8, 12:35pm
Onvacation
2023 Apr 8, 12:35pm
I see no problem with spending taxpayer money to execute the people behind the Wuhan fraud.
7
Patrick
2023 May 22, 8:04pm
Patrick
2023 May 22, 8:04pm
https://sashalatypova.substack.com/p/moderna-history-part-1-the-co-founders
Moderna History, Part 1: The Co-Founders
They are a diverse, inclusive, and colorful bunch from Harvard and MIT.
9
Patrick
2023 Oct 18, 9:59am
Patrick
2023 Oct 18, 9:59am
https://www.coffeeandcovid.com/p/rescinded-wednesday-october-18-2023
💉 As I sat down to a blank screen this morning I said to myself, self, I could use some good news to start off the post. And boom! There it was. As the reality of the market’s nearly-complete rejection of the mRNA shots sank in, Moderna’s stock price continued dropping yesterday, now down over 60% so far this year. The drug marketer has only one product it claims to have developed itself — the unsafe and ineffective covid shot.
Moderna probably has not yet hit the bottom. My suggestion: Sell!
10
richwicks
2023 Oct 18, 10:04am
richwicks
2023 Oct 18, 10:04am
Patrick says
I think Moderna is fucked. MRNA isn't viable. It doesn't work.
I know they are still.pushing the technology but it doesn't work.
Moderna probably has not yet hit the bottom. My suggestion: Sell!
I think Moderna is fucked. MRNA isn't viable. It doesn't work.
I know they are still.pushing the technology but it doesn't work.
11
KgK one
2023 Oct 18, 12:15pm
I bought it for its tech , not for covid but diabeties etc, they need to come up with something hopefully
13
Patrick
2023 Nov 18, 1:31pm
Patrick
2023 Nov 18, 1:31pm
https://twitter.com/VigilantFox/status/1724641530348998662
Moderna ADMITS That DNA Contamination Can Lead to Cancer
• Moderna has a patent that acknowledges RNA is preferable to DNA in vaccines due to risks of insertional mutagenesis, which might activate oncogenes or inhibit tumor suppressor genes, Dr.
@RWMaloneMD
explained.
• A new study up for peer review has found billions of residual DNA fragments in COVID-19 mRNA vaccine vials. In other words, the vials are contaminated with DNA. These findings were not disclosed to the public.
• Additionally, Pfizer, in their documentation to regulatory bodies, omitted information about the presence of SV40 sequences in their vaccine.
• As such, the COVID shots, contaminated with DNA fragments, can cause anything associated with DNA damage — birth defects and cancers being the notable ones.
Biotechnology company Moderna, Inc. (MRNA) reported a profit for the third quarter that plunged 69 percent from last year, reflecting a drop in COVID-19 vaccines sales and higher operating expenses. Both earnings per share and revenues for the quarter missed analysts' expectations.
In pre-market activity on Nasdaq, Moderna shares are plunging $18.52 or 12.46 percent to trade at $130.10.
For the third quarter, the company reported net income of $1.04 billion or $2.53 per share, down from $3.33 billion or $7.70 per share in the prior-year quarter.
On average, 13 analysts polled by Thomson Reuters expected the company to report earnings of $3.29 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter declined to $3.36 billion from last year's $4.97 billion, resulting mainly due to a decline in sales of the company's COVID-19 vaccines. Analysts expected revenues of $3.53 billion for the quarter.
Product sales for the quarter decreased 35 percent to $3.1 billion from last year, primarily driven by lower sales volume due to the timing of market authorizations for our COVID-19 bivalent boosters and the related manufacturing ramp up.
Total operating expenses surged to $2.20 billion from $1.41 billion last year, primarily hurt by a charge of $333 million for inventory write-downs related to COVID-19 products, increased clinical trial-related expenses and increased headcount.
Moderna said it now has 48 programs in development across 45 development candidates, of which 35 are currently in active clinical trials.
Looking ahead, the company has already signed advance purchase agreements or APAs for product sales of approximately $18 billion to 19 billion for anticipated deliveries in 2022 following delay of $2 billion to $3 billion for deliveries into 2023, due to short-term supply constraints.
The confirmed APAs, as well as previously deferred product sales, currently represent $4.5 billion to $5.5 billion in anticipated product sales in 2023. The Company expects additional sales in key markets, including the U.S., E.U., Japan, Middle East, Latin America and Asia Pacific in 2023.
"With $13.6 billion in product sales through the first three quarters of the year, and advance purchase agreements for anticipated delivery this year now expected to produce around $18 to $19 billion of product sales, we continue to have a strong financial position as we prepare for multiple upcoming global product launches," said Stéphane Bancel, Chief Executive Officer of Moderna.
https://markets.businessinsider.com/news/stocks/moderna-stock-plunges-12-as-q3-results-miss-estimates-1031870127